Literature DB >> 22067440

Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue.

Julio C Rojas1, Aleksandra K Bruchey, F Gonzalez-Lima.   

Abstract

This paper provides the first review of the memory-enhancing and neuroprotective metabolic mechanisms of action of methylene blue in vivo. These mechanisms have important implications as a new neurobiological approach to improve normal memory and to treat memory impairment and neurodegeneration associated with mitochondrial dysfunction. Methylene blue's action is unique because its neurobiological effects are not determined by regular drug-receptor interactions or drug-response paradigms. Methylene blue shows a hormetic dose-response, with opposite effects at low and high doses. At low doses, methylene blue is an electron cycler in the mitochondrial electron transport chain, with unparalleled antioxidant and cell respiration-enhancing properties that affect the function of the nervous system in a versatile manner. A major role of the respiratory enzyme cytochrome oxidase on the memory-enhancing effects of methylene blue is supported by available data. The memory-enhancing effects have been associated with improvement of memory consolidation in a network-specific and use-dependent fashion. In addition, low doses of methylene blue have also been used for neuroprotection against mitochondrial dysfunction in humans and experimental models of disease. The unique auto-oxidizing property of methylene blue and its pleiotropic effects on a number of tissue oxidases explain its potent neuroprotective effects at low doses. The evidence reviewed supports a mechanistic role of low-dose methylene blue as a promising and safe intervention for improving memory and for the treatment of acute and chronic conditions characterized by increased oxidative stress, neurodegeneration and memory impairment.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22067440      PMCID: PMC3265679          DOI: 10.1016/j.pneurobio.2011.10.007

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  114 in total

1.  The effect of rotenone on respiration and its point of attack.

Authors:  P E LINDAHL; K E OBERG
Journal:  Exp Cell Res       Date:  1961-03       Impact factor: 3.905

2.  A two-year double-blind crossover trial of the prophylactic effect of methylene blue in manic-depressive psychosis.

Authors:  G J Naylor; B Martin; S E Hopwood; Y Watson
Journal:  Biol Psychiatry       Date:  1986-08       Impact factor: 13.382

3.  Acute extrapyramidal syndrome in methylmalonic acidemia: "metabolic stroke" involving the globus pallidus.

Authors:  R Heidenreich; M Natowicz; B E Hainline; P Berman; R I Kelley; R E Hillman; G T Berry
Journal:  J Pediatr       Date:  1988-12       Impact factor: 4.406

4.  Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases.

Authors:  M W Cleeter; J M Cooper; V M Darley-Usmar; S Moncada; A H Schapira
Journal:  FEBS Lett       Date:  1994-05-23       Impact factor: 4.124

5.  Radiation hormesis: historical perspective and implications for low-dose cancer risk assessment.

Authors:  Alexander M Vaiserman
Journal:  Dose Response       Date:  2010-01-18       Impact factor: 2.658

6.  No evidence for cognitive improvement from oral nicotinamide adenine dinucleotide (NADH) in dementia.

Authors:  M Rainer; E Kraxberger; M Haushofer; H A Mucke; K A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2000       Impact factor: 3.575

7.  Classical conditioning modifies cytochrome oxidase activity in the auditory system.

Authors:  A Poremba; D Jones; F Gonzalez-Lima
Journal:  Eur J Neurosci       Date:  1998-10       Impact factor: 3.386

8.  Cerebrospinal fluid concentrations of idebenone in Friedreich ataxia patients.

Authors:  R Artuch; A Aracil; A Mas; E Monrós; M A Vilaseca; M Pineda
Journal:  Neuropediatrics       Date:  2004-04       Impact factor: 1.947

9.  Inhibition of nitric oxide synthesis by methylene blue.

Authors:  B Mayer; F Brunner; K Schmidt
Journal:  Biochem Pharmacol       Date:  1993-01-26       Impact factor: 5.858

Review 10.  Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.

Authors:  J Pelgrims; F De Vos; J Van den Brande; D Schrijvers; A Prové; J B Vermorken
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

View more
  63 in total

1.  Multimodal Randomized Functional MR Imaging of the Effects of Methylene Blue in the Human Brain.

Authors:  Pavel Rodriguez; Wei Zhou; Douglas W Barrett; Wilson Altmeyer; Juan E Gutierrez; Jinqi Li; Jack L Lancaster; Francisco Gonzalez-Lima; Timothy Q Duong
Journal:  Radiology       Date:  2016-06-28       Impact factor: 11.105

Review 2.  Augmentation of Evidence-Based Psychotherapy for PTSD With Cognitive Enhancers.

Authors:  Marie-France Marin; Sylwia Fowler Lonak; Mohammed R Milad
Journal:  Curr Psychiatry Rep       Date:  2015-06       Impact factor: 5.285

3.  Methylene Blue Reduces Acute Cerebral Ischemic Injury via the Induction of Mitophagy.

Authors:  Yao Di; Yun-Ling He; Tong Zhao; Xin Huang; Kui-Wu Wu; Shu-Hong Liu; Yong-Qi Zhao; Ming Fan; Li-Ying Wu; Ling-Ling Zhu
Journal:  Mol Med       Date:  2015-05-19       Impact factor: 6.354

4.  Methylene Blue Protects Against Sevoflurane-Induced Cognitive Dysfunction by Suppressing Drp1 deSUMOylation in Aged Mice.

Authors:  Feng Zheng; Peng Fang; Jing Chang; Min Chen; Qi Zhong; Ting Chen; Chang Chen; Zongze Zhang
Journal:  Neurochem Res       Date:  2020-02-01       Impact factor: 3.996

5.  Methylene blue does not bypass Complex III antimycin block in mouse brain mitochondria.

Authors:  Artem P Gureev; Ekaterina A Shaforostova; Vasily N Popov; Anatoly A Starkov
Journal:  FEBS Lett       Date:  2019-02-20       Impact factor: 4.124

Review 6.  Pharmacological treatment of anxiety disorders: current treatments and future directions.

Authors:  Frank J Farach; Larry D Pruitt; Janie J Jun; Alissa B Jerud; Lori A Zoellner; Peter P Roy-Byrne
Journal:  J Anxiety Disord       Date:  2012-08-15

7.  Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity.

Authors:  Cliona Stack; Shari Jainuddin; Ceyhan Elipenahli; Meri Gerges; Natalia Starkova; Anatoly A Starkov; Mariona Jové; Manuel Portero-Otin; Nathalie Launay; Aurora Pujol; Navneet Ammal Kaidery; Bobby Thomas; Davide Tampellini; M Flint Beal; Magali Dumont
Journal:  Hum Mol Genet       Date:  2014-02-20       Impact factor: 6.150

8.  Methylene blue does not reverse existing neurofibrillary tangle pathology in the rTg4510 mouse model of tauopathy.

Authors:  Tara L Spires-Jones; Taylor Friedman; Rose Pitstick; Manuela Polydoro; Allyson Roe; George A Carlson; Bradley T Hyman
Journal:  Neurosci Lett       Date:  2014-01-21       Impact factor: 3.046

9.  Methylene blue potentiates stimulus-evoked fMRI responses and cerebral oxygen consumption during normoxia and hypoxia.

Authors:  Shiliang Huang; Fang Du; Yen-Yu I Shih; Qiang Shen; F Gonzalez-Lima; Timothy Q Duong
Journal:  Neuroimage       Date:  2013-01-26       Impact factor: 6.556

10.  Revisiting the physiological effects of methylene blue as a treatment of cyanide intoxication.

Authors:  Philippe Haouzi; Maxime Gueguinou; Takashi Sonobe; Annick Judenherc-Haouzi; Nicole Tubbs; Mohamed Trebak; Joseph Cheung; Frederic Bouillaud
Journal:  Clin Toxicol (Phila)       Date:  2018-02-16       Impact factor: 4.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.